This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Gilli, F Articles by Bertolotto, A Search for Related Content PubMed PubMed Citation Articles by Gilli, F Articles by Bertolotto, A Social Bookmarking                         What's this?

Biological markers of interferon-beta therapy: comparison among interferon-stimulated genes MxA, TRAIL and XAF-1

Centro di Riferimento Regionale Sclerosi Multipla (CReSM) & Neurobiologia Clinica, ASO S. Luigi Gonzaga, Orbassano, Torino, Italy

F Marnetto

Centro di Riferimento Regionale Sclerosi Multipla (CReSM) & Neurobiologia Clinica, ASO S. Luigi Gonzaga, Orbassano, Torino, Italy

M Caldano

Centro di Riferimento Regionale Sclerosi Multipla (CReSM) & Neurobiologia Clinica, ASO S. Luigi Gonzaga, Orbassano, Torino, Italy

A Sala

Centro di Riferimento Regionale Sclerosi Multipla (CReSM) & Neurobiologia Clinica, ASO S. Luigi Gonzaga, Orbassano, Torino, Italy

S Malucchi

Centro di Riferimento Regionale Sclerosi Multipla (CReSM) & Neurobiologia Clinica, ASO S. Luigi Gonzaga, Orbassano, Torino, Italy

M Capobianco

Centro di Riferimento Regionale Sclerosi Multipla (CReSM) & Neurobiologia Clinica, ASO S. Luigi Gonzaga, Orbassano, Torino, Italy

A Bertolotto

Centro di Riferimento Regionale Sclerosi Multipla (CReSM) & Neurobiologia Clinica, ASO S. Luigi Gonzaga, Orbassano, Torino, Italy, sclerosi.multipla{at}sanluigi.piemonte.it

Biological activity of interferon-beta (IFNß) can be assessed by measuring IFN-stimulated genes (ISGs). Among them, myxovirus resistance protein A (MxA) appears to have the highest specificity, but it has no role in the pathogenesis of multiple sclerosis (MS). To investigate the reliability of MxA as a biomarker, we compared its expression to that of two other ISGs: TNF-related apoptosis-inducing ligand (TRAIL) and X-linked inhibitor of apoptosis factor-1 (XAF-1). Both were shown to be involved in immunoregulatory mechanisms and might play a role in MS. Quantitative-PCR measurements were performed in peripheral blood mononuclear cells from 73 MS patients after short-term and long-term treatment with IFNß. A time-dependent response for multiple ISGs was observed in all patients after short-term treatment. In contrast, long-term treatment induced concurrent inhibition of ISGs in 12.3% (9/73) of patients, in whom neutralizing antibodies (NAbs) were detectable. Besides, 22% (16/73) of chronically treated patients showed a non-NAbs-related abrogation of TRAIL expression. In summary, 1) MxA expression was significantly higher than both TRAIL and XAF-1, and 2) MxA was the most sensitive gene to detect decreased bioavailability due to NAbs. These findings identify MxA as an appropriate biomarker for IFNß, although there is no evidence for a functional role of it in MS.

Key Words: biomarkers • interferon-beta • interferon-stimulated-genes • ISG • MxA • TRAIL • XAF-1

Multiple Sclerosis, Vol. 12, No. 1, 47-57 (2006)
DOI: 10.1191/135248506ms1245oa


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				A. R. Pachner, J. D. Warth, A. Pace, S. Goelz, and On behalf of the INSIGHT investigators Effect of neutralizing antibodies on biomarker responses to interferon beta: The INSIGHT study Neurology, November 3, 2009; 73(18): 1493 - 1500. [Abstract] [Full Text] [PDF]

				P. Soelberg Sorensen Review: Neutralizing antibodies against interferon-beta Therapeutic Advances in Neurological Disorders, September 1, 2008; 1(2): 125 - 141. [Abstract] [PDF]

				S. Malucchi, F. Gilli, M. Caldano, F. Marnetto, P. Valentino, L. Granieri, A. Sala, M. Capobianco, and A. Bertolotto Predictive markers for response to interferon therapy in patients with multiple sclerosis Neurology, March 25, 2008; 70(13_Part_2): 1119 - 1127. [Abstract] [Full Text] [PDF]

				A Sominanda, J Hillert, and A Fogdell-Hahn In vivo bioactivity of interferon-beta in multiple sclerosis patients with neutralising antibodies is titre-dependent J. Neurol. Neurosurg. Psychiatry, January 1, 2008; 79(1): 57 - 62. [Abstract] [Full Text] [PDF]

				R. A Farrell and G. Giovannoni Measuring and management of Anti-Interferon Beta Antibodies in subjects with Multiple Sclerosis Multiple Sclerosis, June 1, 2007; 13(5): 567 - 577. [Abstract] [PDF]

				N. Somani, M. Martinka, R. I. Crawford, J. P. Dutz, and J. K. Rivers Treatment of Atypical Nevi With Imiquimod 5% Cream Arch Dermatol, March 1, 2007; 143(3): 379 - 385. [Abstract] [Full Text] [PDF]